Key biosensor components of Archer’s lab-on-a-chip device miniaturised to nanosize chip formats, a requirement for successful biochip development. • Archer team grows, introducing world-class expertise and capabilities spanning nanotechnology, advanced materials, and molecular biology. • The Company is utilising over $150 million of sophisticated chip building facilities in Australia to manufacture its graphene-based biochip technology. • Lab-on-a-chip devices form part of the multibillion dollar deep-tech economy, catalysed by the global need for point of care medical diagnostics and testing†,‡.
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.